Successful long-term use of sitagliptin for the treatment of new-onset diabetes mellitus after solid organ transplantation: A case report

Transplantation Proceedings

Volumn 43, Issue 5, 2011, Pages 2113-2115

  Pinelli, N R ^a   Nemerovski, C W ^a   Koelling, T M ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE; CORTICOSTEROID; HEMOGLOBIN A1C; METFORMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; REPAGLINIDE; SITAGLIPTIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOMYOPATHY; CARDIOVASCULAR SYMPTOM; CASE REPORT; DIABETES MELLITUS; DIET RESTRICTION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEFT VENTRICULAR ASSIST DEVICE; LONG TERM CARE; MAINTENANCE THERAPY; MALE; NEW ONSET DIABETES MELLITUS; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; WOUND INFECTION;

DIABETES MELLITUS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PYRAZINES; TRIAZOLES;

EID: 79959401289     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.02.059     Document Type: Article

References (15)

1. V. Montori, A. Basu, and P.J. Erwin Posttransplantation diabetes: a systematic review of the literature Diabetes Care 5 2002 583
2. K.A. Bodziak, and D.E. Hricik New-onset diabetes mellitus after solid organ transplantation Transpl Int 22 2009 519
3. C.F. Deacon, A.H. Johnson, and J.J. Holst Degradation of glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects Diabetes 44 1995 1126
4. P. Aschner, M.S. Kipnes, and J.K. Lunceford Effect of dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 29 2006 2632
5. B. Charbonnel, A. Karasik, and J. Liu Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care 29 2006 2638
6. J. Rosenstock, R. Brazg, and P.J. Andryuk Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: 24 week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 28 2006 1556
7. I. Raz, M. Hanefeld, and L. Xu Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus Diabetologia 49 2006 2564
8. B.J. Goldstein, M.N. Feinglos, and J.K. Lunceford Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes Care 30 2007 1979
9. K. Hermansen, M. Kipnes, and E. Luo Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin Diabetes Obes Metab 9 2007 733
10. M.A. Nauck, G. Meininger, and D. Sheng Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial Diabetes Obes Metab 9 2007 194
11. S. Stewart, G.L. Winters, and M.C. Fishbein Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection: ISHLT consensus report J Heart Lung Transplant 24 2005 1710
12. American Diabetes Association Standards of Medical Care in Diabetes-2011 Diabetes Care 34 2011 S11
13. D. Odegaard, J. Lane, and C. Haire Sitagliptin use in kidney transplant recipients: effect on immunosuppressant levels (abstract) Diabetes 58 suppl 1 2009 A646
14. J. Mu, J. Woods, and Y.P. Zhou Chronic inhibition of dipeptidyl peptidase-4 with sitagliptin analog preserves pancreatic beta-call mass and function in a rodent model of type 2 diabetes Diabetes 55 2006 1695
15. J. Mu, A. Petrov, and G.J. Eiermann Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes Eur J Pharmacol 623 2009 148